Method of treating cancer by administering chimeric antigen receptor comprising anti-GCC antibody

US9662405B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9662405-B2
Application numberUS-201514879936-A
CountryUS
Kind codeB2
Filing dateOct 9, 2015
Priority dateApr 26, 2012
Publication dateMay 30, 2017
Grant dateMay 30, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of treating a subject who has been diagnosed as having cancer comprising cancer cells that express guanylyl cyclase C (GCC), the method comprising administering to said subject a therapeutically effective amount of T cells that express a chimeric antigen receptor comprising a light chain variable region and a heavy chain variable region of an anti-GCC antibody molecule, the chimeric antigen receptor comprising: heavy chain variable region Amino Acid Sequence SEQ ID NO:3 from anti-GCC antibody MS20, and light chain variable region Amino Acid Sequence SEQ ID NO:4 from anti-GCC antibody MS20; wherein the chimeric antigen receptor binds to human GCC. 2. The method of claim 1 , wherein the cancer is metastatic colorectal cancer, primary and/or metastatic esophageal cancer, or primary and/or metastatic stomach cancer. 3. The method of claim 1 , wherein the cancer is metastatic colorectal cancer. 4. The method of claim 1 , wherein the cancer is primary and/or metastatic esophageal. 5. The method of claim 1 , wherein the cancer is primary and/or metastatic stomach cancer.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9662405B2 cover?
Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides th…
Who is the assignee on this patent?
Univ Jefferson
What technology area does this patent fall under?
Primary CPC classification C07K16/40. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).